Emergent BioSolutions (EBS) Non-Current Deferred Tax Liability (2013 - 2026)

Emergent BioSolutions' Non-Current Deferred Tax Liability history runs 11 years deep, the most recent figure standing at $33.3 million for Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 44.87% year-over-year to $33.3 million in Q1 2026; TTM through Mar 2026 was $33.3 million, a 44.87% decrease from a year earlier, with the FY2025 full-year figure at $37.8 million, down 9.35% from the prior year.
• Non-Current Deferred Tax Liability eased to $33.3 million in Q1 2026 per EBS's latest filing, from $37.8 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $125.4 million in Q4 2022 and bottomed at $33.3 million in Q1 2026.
• The 5-year median for Non-Current Deferred Tax Liability is $47.2 million (2023), against an average of $59.5 million.
• Across the five-year window, Non-Current Deferred Tax Liability surged 114.91% in 2022 and tumbled 62.36% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $125.4 million in 2022, then tumbled by 62.36% to $47.2 million in 2023, then fell by 11.65% to $41.7 million in 2024, then declined by 9.35% to $37.8 million in 2025, then retreated by 11.9% to $33.3 million in 2026.
• Per Business Quant, the three latest EBS Non-Current Deferred Tax Liability figures stand at $33.3 million (Q1 2026), $37.8 million (Q4 2025), and $36.3 million (Q3 2025).